surmount-1 tirzepatide Nutritional status with in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials Compounded Tirzepatide

Carbapenems thus provide a double benefit, lowering levels of both the parent drug and active metabolites

Tirzepatide (Mounjaro/Zepbound) : fino al 26% (SURMOUNT-1 e SURMOUNT-5)

These observations call for renewed clinical efforts to investigate the merits of restoring the microbiota through FMT as a complementary strategy to MS treatment, and clinical trials are ongoing

doi: 10.1136/bmj.c869 Summary Keywords obesity, GLP-1, GLP-1 receptor analog, exenatide, pediatrics, glycemic control, GLP-1 receptor agonist, treatment Citation Stenlid R, Cerenius SY, Wen Q, Aydin BK, Manell H, Chowdhury A, Kristinsson H, Ciba I, Gjessing ES, Mrwald K, Gomahr J, Heu V, Weghuber D, Forslund A and Bergsten P (2023) Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control